New! Sign up for our free email newsletter.
Science News
from research organizations

Novel HIV vaccine regimen provides robust protection in non-human primates

Date:
July 2, 2015
Source:
Beth Israel Deaconess Medical Center
Summary:
A new study shows than an HIV-1 vaccine regimen, involving a viral vector boosted with a purified envelope protein, provided complete protection in half of the vaccinated non-human primates (NHPs) against a series of six repeated challenges with simian immunodeficiency virus (SIV), a virus similar to HIV that infects NHPs.
Share:
FULL STORY

A new study led by scientists at Beth Israel Deaconess Medical Center (BIDMC) shows that an HIV-1 vaccine regimen, involving a viral vector boosted with a purified envelope protein, provided complete protection in half of the vaccinated non-human primates (NHPs) against a series of six repeated challenges with simian immunodeficiency virus (SIV), a virus similar to HIV that infects NHPs. These findings are published online today in Science.

Based on these pre-clinical data, the HIV-1 version of this vaccine regimen is now being evaluated in an ongoing Phase 1/2a international clinical study sponsored by Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

"We previously showed that adenovirus vector-based HIV-1 vaccine candidates offered partial protection against SIV when given alone," said lead author Dan H. Barouch, M.D., Ph.D., director of the Center for Virology and Vaccine Research at BIDMC and professor of medicine at Harvard Medical School. The paper describes two new studies in which investigators evaluated the protective efficacy of an adenovirus serotype 26 (Ad26) vectored vaccine boosted with a purified envelope protein.

The results demonstrate that viral vector priming plus protein boosting resulted in complete protection in half of the vaccinated animals. "This shows improvement over our previous results," said Barouch, who is also a steering committee member of the Ragon Institute of MGH, MIT, and Harvard. "Moreover, protection correlated with the magnitude and polyfunctionality of antibody responses. The data show the potential utility of envelope protein boosting following Ad26 priming."

"Bringing the global HIV epidemic under control requires new tools, bold strategies and collaboration among a number of stakeholders," said Hanneke Schuitemaker, one of the study authors and vice president, Viral Vaccines Discovery and Translational Medicine, Janssen. "In line with our company's commitment to address global health needs, we are committed to working with leading experts to develop a preventative HIV vaccine and our team is excited to advance this program into human clinical studies."


Story Source:

Materials provided by Beth Israel Deaconess Medical Center. Note: Content may be edited for style and length.


Journal Reference:

  1. Dan H. Barouch, Galit Alter, Thomas Broge, Caitlyn Linde, Margaret E. Ackerman, Eric P. Brown, Erica N. Borducchi, Kaitlin M. Smith, Joseph P. Nkolola, Jinyan Liu, Jennifer Shields, Lily Parenteau, James B. Whitney, Peter Abbink, David M. Ng’ang’a, Michael S. Seaman, Christy L. Lavine, James R. Perry, Wenjun Li, Arnaud D. Colantonio, Mark G. Lewis, Bing Chen, Holger Wenschuh, Ulf Reimer, Michael Piatak, Jeffrey D. Lifson, Scott A. Handley, Herbert W. Virgin, Marguerite Koutsoukos, Clarisse Lorin, Gerald Voss, Mo Weijtens, Maria G. Pau, and Hanneke Schuitemaker. Protective efficacy of adenovirus-protein vaccines against SIV challenges in rhesus monkeys. Science, 2 July 2015 DOI: 10.1126/science.aab3886

Cite This Page:

Beth Israel Deaconess Medical Center. "Novel HIV vaccine regimen provides robust protection in non-human primates." ScienceDaily. ScienceDaily, 2 July 2015. <www.sciencedaily.com/releases/2015/07/150702151258.htm>.
Beth Israel Deaconess Medical Center. (2015, July 2). Novel HIV vaccine regimen provides robust protection in non-human primates. ScienceDaily. Retrieved March 18, 2024 from www.sciencedaily.com/releases/2015/07/150702151258.htm
Beth Israel Deaconess Medical Center. "Novel HIV vaccine regimen provides robust protection in non-human primates." ScienceDaily. www.sciencedaily.com/releases/2015/07/150702151258.htm (accessed March 18, 2024).

Explore More

from ScienceDaily

RELATED STORIES